Latest

GLP-1

This shows a person holding their head in pain.

·June 24, 2025·3 min read

GLP-1 Drug Cuts Migraine Days in Half

A new study finds that the diabetes drug liraglutide significantly reduced monthly migraine days in patients with obesity and chronic migraine. Participants reported an average of 11 fewer headache days per month, alongside improved disability scores and quality of life.

Featured Neuroscience

·May 26, 2025·4 min read

Brainstem Neurons Hold Key to Semaglutide’s Weight Loss Effects

Researchers have identified a specific group of brainstem neurons that mediate the appetite-reducing and weight-loss effects of semaglutide without triggering side effects like nausea. In mice, activating these neurons led to reduced food intake and fat loss, mimicking the drug’s benefits.

Featured Neuroscience

·May 13, 2025·6 min read

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Trial

In a 72-week clinical trial, tirzepatide (Zepbound) led to significantly greater weight loss than semaglutide (Wegovy), with participants losing an average of 20.2% of their body weight versus 13.7%. The study directly compared the two drugs at their highest doses in people with obesity but without diabetes.

Featured Neuroscience Psychology

·April 18, 2025·5 min read

Potential Depression Risk Linked to Ozempic-Like Drugs

A new international study reveals a possible connection between GLP1 receptor agonists—used in drugs like Ozempic—and increased risk of depression and suicidal ideation, especially in people with low dopamine function. Researchers used advanced pharmacogenomic tools to identify genetic pathways that may be vulnerable to dopamine dysregulation when exposed to these medications.

Featured Neurology Neuroscience

·April 16, 2025·5 min read

Ozempic Linked to Lower Alzheimer’s Risk

A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias. Researchers analyzed Medicare data and found that patients taking these drugs had significantly lower rates of cognitive decline compared to those using other glucose-lowering medications.

This shows the outline of a person and a brain.

Featured Neuroscience

·January 20, 2025·6 min read

GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits, including reduced risks of addiction, Alzheimer’s, and dementia. However, they also pose risks for pancreatitis and kidney conditions, emphasizing the need for careful monitoring.

Featured Neuroscience Psychology

·September 4, 2024·5 min read

No Link Found Between Ozempic and Suicide Risk

A new study has found no evidence that GLP-1 analogues, common diabetes drugs, increase the risk of suicide, self-harm, or related mental health issues. Researchers analyzed data from around 300,000 people treated with these medications and found no clear link between the drugs and mental health risks.

Featured Neurology Neuroscience

·July 30, 2024·4 min read

GLP-1 Drug Slows Alzheimer’s Cognitive Decline

A recent study suggests that a GLP-1 drug, liraglutide, may protect the brains of people with mild Alzheimer’s disease, slowing cognitive decline by 18% over one year. This effect is likely due to the drug’s ability to reduce brain inflammation, improve insulin resistance, and lower the impact of Alzheimer’s biomarkers.

Featured Genetics Neuroscience

·July 15, 2024·5 min read

Adjusting Proteins Increases Ozempic’s Effectiveness

Adjusting melanocortin proteins in the brain enhances the effectiveness of GLP-1 diabetes and weight-loss drugs. By inhibiting MC3R or activating MC4R, mice showed increased sensitivity to these drugs, leading to more significant weight loss and reduced feeding without additional side effects.

Featured Neuroscience

·June 27, 2024·3 min read

Ozempic Boost Fullness Pre-Meal via Hypothalamus

A new study shows GLP-1 receptor agonists increase pre-meal fullness by activating neurons in the dorsomedial hypothalamus. This mechanism helps prevent overeating, offering insights into obesity treatment. The research highlights how GLP-1 impacts food perception and hypothalamic responses to food cues, enhancing satiation before food intake.

This shows an older man and a brain scan.

Featured Neurology Neuroscience

·June 21, 2024·4 min read

Ozempic May Reduce Alzheimer’s Risk

GLP-1 agonists like Ozempic reduce the risk of dementia in type 2 diabetes patients. The research followed over 88,000 individuals for up to ten years, showing a 30% lower risk compared to sulfonylureas and a 23% lower risk compared to DPP-4 inhibitors. These findings can guide doctors in selecting medications for older diabetes patients. However, further randomized trials are needed to confirm these results.

Featured Neuroscience Psychology

·June 3, 2024·3 min read

Ozempic May Reduce Alcohol Abuse Risk

Diabetes drugs Wegovy and Ozempic, containing semaglutide, significantly reduce the incidence and recurrence of alcohol-use disorder (AUD). Analyzing health records, researchers observed a 50% to 56% decrease in AUD among patients treated with semaglutide.

1 2

GLP-1

GLP-1 Drug Cuts Migraine Days in Half

Brainstem Neurons Hold Key to Semaglutide’s Weight Loss Effects

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Trial

Potential Depression Risk Linked to Ozempic-Like Drugs

Ozempic Linked to Lower Alzheimer’s Risk

GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks

No Link Found Between Ozempic and Suicide Risk

GLP-1 Drug Slows Alzheimer’s Cognitive Decline

Adjusting Proteins Increases Ozempic’s Effectiveness

Ozempic Boost Fullness Pre-Meal via Hypothalamus

Ozempic May Reduce Alzheimer’s Risk

Ozempic May Reduce Alcohol Abuse Risk

Boosting Sleep Ripples Helps Preserve Memories Normally Forgotten

Stress Levels Predict Cannabis Use

Losing Myelin Scrambles the Brain’s Sensory Signals

AI Turns Simple EEG Scans Into Accurate Dementia Detectors

Subscribe